Abetalipoporteinemia
Methodology & AI Transparency ⓘ
Abetalipoporteinemia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code E78.6 in Cholesterol & Lipids, Abetalipoporteinemia requires fasting lipid fractionation [Abetalipoporteinemia E78.6] so specialists can calibrate treatment intensity against Lipoprotein(a) [Lp(a)] [Abetalipoporteinemia E78.6] benchmarks.
- 2 Real-world patient consensus: Clinical coding for Abetalipoporteinemia uses ICD-10 E78.6 across Cholesterol & Lipids specialty care.
- 3 Typical cash cost range: Differential triage of Abetalipoporteinemia (E78.6) utilizes fasting lipid fractionation [Abetalipoporteinemia E78.6].
- 4 Top reported side effects / signs: Follow-up benchmark in Abetalipoporteinemia: maintaining Lipoprotein(a) [Lp(a)] [Abetalipoporteinemia E78.6] within < 75 nmol/L (E78.6).
Ask our AI Specialists anything about Abetalipoporteinemia
What Is Abetalipoporteinemia?
Cataloged under federal diagnostic code E78.6 in Cholesterol & Lipids, Abetalipoporteinemia requires fasting lipid fractionation [Abetalipoporteinemia E78.6] so specialists can calibrate treatment intensity against Lipoprotein(a) [Lp(a)] [Abetalipoporteinemia E78.6] benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Abetalipoporteinemia (E78.6) features remnant cholesterol accumulation [Abetalipoporteinemia E78.6]. therapeutic stabilization in cholesterol & lipids is verified against Apolipoprotein B (ApoB) [Abetalipoporteinemia E78.6].
Common Symptoms & Clinical Signs
- • Presentation of Abetalipoporteinemia (E78.6): elevated triglyceride-to-HDL ratio [Abetalipoporteinemia E78.6]
- • Secondary Abetalipoporteinemia clinical sign: premature family history in Abetalipoporteinemia (E78.6: of coronary stenting,)
- • Symptom flares in Abetalipoporteinemia correlating with Lipoprotein(a) [Lp(a)] [Abetalipoporteinemia E78.6] deviation outside < 75 nmol/L (E78.6)
- • Functional cholesterol & lipids impact requiring fasting lipid fractionation [Abetalipoporteinemia E78.6] evaluation (E78.6)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Abetalipoporteinemia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E78.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cholesterol, Triglycerides & Lipids | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Lipoprotein(a) [Lp(a)] [Abetalipoporteinemia E78.6] | < 75 nmol/L (E78.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Abetalipoporteinemia E78.6] | < 70 mg/dL (< 55 mg/dL high risk) (E78.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: LDL Cholesterol [Abetalipoporteinemia E78.6] | < 85 mg/dL (E78.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Abetalipoporteinemia
Treatment selection for Abetalipoporteinemia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Abetalipoporteinemia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Triple Therapy With Telmisartan, Amlodipine, and Among 148 patients, the changes in msSBP from baseline after 8 weeks of treatment were a mean (SD) of -24.41 (2.38) versus -9.31 (2.36) mm Hg in the telmisartan/amlodipine/rosuvastatin and telmisartan/rosuvastatin groups,... Clinical therapeutics • 2019-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 30665829 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with In adults with FCS, olezarsen significantly lowers apoC-III in all major lipoprotein pools, particularly in total apoB and apoA-I. Atherosclerosis • 2025-09-15 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 40706406 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of self-emulsifying formulation of highly purified Non-inferiority of MND-2119 2 g/day to EPA-E 1.8 g/day for efficacy, and superiority of MND-2119 4 g/day over MND-2119 2 g/day for efficacy were verified. Journal of clinical lipidology • 2022-01-15 • Phase III Randomized Trial | N = 145 | 88/100 | PMID 35871058 ↗ |
| Can This Approach Help? Inside the Latest Research on Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Reductions in total cholesterol, LDL-C, apolipoprotein B, the apolipoprotein B/A1 ratio, and non-HDL-C were not different between the R5 + E10 and R10 treatment groups (all, P > 0.017), the R5 + E10 and R20 treatment groups... Clinical therapeutics • 2019-12-15 • Phase III Randomized Trial | N = 68 | 88/100 | PMID 31727361 ↗ |
| New Insights on Benefits and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk: What a 871-Participant Study Found Intensive lipid-lowering therapy with rosuvastatin 40 mg/day provided greater LDL-C-lowering efficacy than atorvastatin 80 mg/day, enabling more patients to achieve LDL-C goals. Atherosclerosis • 2007-10-15 • Randomized Controlled Trial | N = 871 | 87/100 | PMID 17229426 ↗ |
Abetalipoporteinemia Patient Community & “People Like Me” Threads
Filter Abetalipoporteinemia community threads and patient logs by age, biological sex, dosage, and treatment duration.